NCT05181215已完成1 期
A Single-Dose, Randomized, Open-Label, Two-Way Crossover, Bioequivalence Study of Bafiertam (Monomethyl Fumarate) 190 mg and Vumerity® (Diroximel Fumarate) 462 mg Delayed-Release Capsules in Fasting Healthy Male and Female Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- The Bioequivalent (BE) Comparison of AUC0-inf of Monomethyl Fumarate (MMF) Between Treatments
研究概览
简要总结
A single-dose, randomized, open-label, two-way crossover, two-period, two-sequence, two-treatment, single-center, bioequivalence study of Bafiertam and Vumerity.
详细描述
A single-dose, randomized, open-label, two-way crossover, two-period, two-sequence, two-treatment, single-center to assess the bioequivalence of Bafiertam (Monomethyl Fumarate) 190 mg (administered as 2 x 95 mg) Delayed-Release Capsules and Vumerity® (Diroximel Fumarate) 462 mg (Administered as 2 x 231 mg) Delayed-Release Capsules as assessed by plasma monomethyl fumarate concentrations in 40 healthy, non-smoking, male, and non-pregnant female volunteers under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, non-smoking (at least for 6 months prior to first study drug administration) male and non-pregnant female volunteers, 18 years of age and older.
- •BMI that is within 18.5-33.0 kg/m², inclusive.
- •Healthy, according to the medical history, ECG, vital signs, laboratory results, and physical examination as determined by the PI/Sub-Investigator.
- •Systolic blood pressure between 95-140 mmHg, inclusive, and diastolic blood pressure between 55-90 mmHg, inclusive, and heart rate between 50- 100 bpm, inclusive, unless deemed otherwise by the PI/Sub-Investigator.
- •Clinical laboratory values within BPSUSA's most recent acceptable laboratory test range, and/or values are deemed by the PI/Sub-Investigator as "Not Clinically Significant".
- •Ability to comprehend and be informed of the nature of the study, as assessed by BPSUSA staff. Capable of giving written informed consent prior to receiving any study medication. Must be able to communicate effectively with clinic staff.
- •Ability to fast for at least 14 hours and consume standard meals.
- •Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements.
- •Agree not to have a tattoo or body piercing until the end of the study.
- •Agree not to receive a vaccination (live attenuated vaccine) during the study and until 30 days after the study has ended (last study procedure).
- •Agree not to drive or operate heavy machinery if feeling dizzy or drowsy following study drug administration until full mental alertness is regained.
- •Female subjects must fulfill at least one of the following: Be surgically sterile for a minimum of 6 months; Post-menopausal for a minimum of 1 year; Agree to avoid pregnancy and use a medically acceptable method of contraception from at least 30 days prior to the study until 90 days after the study has ended (last study procedure).
- •Male subjects who are able to father children must agree to use medically acceptable methods of contraception during the study and for 90 days after his last study drug administration.
排除标准
- •Known history or presence of any clinically significant hepatic (e.g., hepatic impairment), renal/genitourinary (e.g., renal impairment), gastrointestinal, cardiovascular (supraventricular extrasystoles, atrioventricular block first degree, angina pectoris), cerebrovascular, pulmonary, endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological or hematological disease or condition unless determined as not clinically significant by the PI/Sub-Investigator.
- •Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g., chronic diarrhea, inflammatory bowel disease), unresolved gastrointestinal symptoms (e.g., diarrhea, vomiting), or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug experienced within 7 days prior to first study drug administration, as determined by the PI/Sub-Investigator.
- •Presence of any clinically significant illness within 30 days prior to first dosing, as determined by the PI/Sub-Investigator.
- •Presence of any significant physical or organ abnormality as determined by the PI/Sub-Investigator.
- •A positive test result for any of the following: HIV, Hepatitis B surface antigen, Hepatitis C, drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines), alcohol test and cotinine. Positive pregnancy test for female subjects.
- •Known history or presence of: Alcohol or Drug abuse or dependence; Hypersensitivity or idiosyncratic reaction to monomethyl fumarate, diroximel fumarate, dimethyl fumarate, Bafiertam, Vumerity, their excipients, and/or related substances; Lymphocyte count <1.5x 10^9/L; Liver injury; Gastroenteritis; Protein in urine / Fanconi syndrome; Progressive multifocal leukoencephalopathy; Serious opportunistic infections, fungal infections; Food allergies and/or presence of any dietary restrictions unless deemed by the PI/Sub-I as "Not Clinically Significant"; Severe allergic reactions.
- •Intolerance to and/or difficulty with blood sampling through venipuncture.
- •Abnormal diet patterns (for any reason) during the four weeks preceding the study, including fasting, high protein diets, etc.
- •Individuals who have donated, in the days prior to first study drug administration: 50-499 mL of blood in the previous 30 days; 500 mL or more in the previous 56 days.
- •Donation of plasma by plasmapheresis within 7 days prior to first study drug administration.
- •Individuals who have participated in another clinical trial or who received an investigational drug within 30 days prior to first study drug administration.
- •Consumption of food or beverages containing caffeine/methylxanthines, poppy seeds and/or alcohol within 48 hours before dosing and containing grapefruit and/or pomelo within 10 days prior to first study drug administration.
- •Use of any prescription medication within 14 days prior to first study drug administration (except for hormonal contraceptives).
- •Use of antineoplastic, immunosuppressive, or immune-modulating therapies and fumaric acid derivatives, nephrotoxic drugs within 14 days prior to first study drug administration.
- •Use of any over-the-counter medications (including oral multivitamins, herbal, and/or dietary supplements) within 14 days prior to first study drug administration (except for spermicidal/barrier contraceptive products).
- •Individuals having undergone any major surgery within 6 months prior to the start of the study unless deemed otherwise by PI/Sub-Investigator.
- •Difficulty with swallowing the whole capsule.
- •Women who are pregnant or lactating.
- •Unable or unwilling to provide informed consent.
- •Have had a tattoo or body piercing within 30 days prior to first study drug administration
研究组 & 干预措施
Vumerity
Active Comparator
462 mg (2 x 231 mg) delayed-release capsules
干预措施: Diroximel Fumarate 462 mg (Drug)
Bafiertam
Experimental
190 mg (2 x 95 mg) delayed-release capsules
干预措施: Monomethyl Fumarate 190 Mg (Drug)
结局指标
主要结局
The Bioequivalent (BE) Comparison of AUC0-inf of Monomethyl Fumarate (MMF) Between Treatments
时间窗: 24 hours
Pharmacokinetics: Plasma concentrations of MMF will be determined and used to calculate AUC0-inf MMF for each treatment. Venous blood samples were collected immediately prior to dosing (time 0), and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24 hours postdose.
The BE Comparison of Cmax of Monomethyl Fumarate (MMF) Between Treatments
时间窗: 24 hours
Pharmacokinetics: Plasma concentrations of MMF will be determined and used to calculate Cmax of MMF for each treatment. Venous blood samples were collected immediately prior to dosing (time 0), and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24 hours postdose.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg Under Fed and Fasting ConditionsType2 DiabetesNCT04070794LG Chem24
已完成
1 期
A Single Dose, Randomized, Open-label, Two-way Crossover Comparative Bioavailability Study of Generic Levetiracetam 1000 mg Film-coated Tablets and Two Tablets of Reference Levetiracetam (Keppra) 500 mg Film-coated Tablets in Healthy Thai Volunteers under Fasting ConditionsHealthy VolunteersTCTR20180517001Intega (Thailand) Co., Ltd.26
已完成
不适用
Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy VolunteersChronic Hepatitis bNCT03847246Chia Tai Tianqing Pharmaceutical Group Co., Ltd.26
已完成
1 期
Bioequivalence - Duodart Against Avodart & OmnicProstatic HyperplasiaNCT01657851GlaxoSmithKline35
已完成
1 期
Safety and Pharmacokinetic Characteristics of DKF-313HealthyBenign Prostate HyperplasiaNCT02352311Dongkook Pharmaceutical Co., Ltd.54